Tatyana Korolenko1, Thomas P Johnston2, Alexander P Lykov3, Alexandra B Shintyapina4, Marina V Khrapova1, Natalya V Goncharova1, Erik Korolenko5, Nataliya P Bgatova3, Eva Machova6, Zuzana Nescakova6, Ludmila V Sakhno7. 1. Scientific Research Institute of Physiology and Basic Medicine, Novosibirsk, Russia. 2. Division of Pharmaceutical Sciences, University of Missouri-Kansas City, Kansas City, MO, USA. 3. Scientific Institute of Clinical and Experimental Lymphology, Novosibirsk, Russia. 4. Institute of Molecular Biology and Biophysics, Novosibirsk, Russia. 5. University Canada West, Vancouver, BC, Canada. 6. Institute of Chemistry, Slovak Academy of Sciences, Bratislava, Slovakia. 7. Scientific Institute of Fundamental and Clinical Immunology, Novosibirsk, Russia.
Abstract
OBJECTIVES: We evaluated the hypolipidaemic effect of mannan Candida albicans serotype A, relative to atorvastatin, in a mouse model of hyperlipidaemia. METHODS: Mannan serotype A was investigated in vitro and in vivo to determine its effects on macrophage proliferation, nitric oxide (NO) production by cultured macrophages, serum and liver lipids, changes in liver morphology and serum chitotriosidase activity and its expression in the liver. KEY FINDINGS: Mannan serotype A stimulates the macrophage proliferation and NO production in murine peritoneal macrophages in vitro. The activity of serum chitotriosidase (an enzyme released from the activated macrophages) was found to be significantly increased in P-407-induced hyperlipidaemic mice pretreated with low-dose mannan compared with mice administered P-407 only. Mannan treatment in mice was shown to significantly increase the chitotriosidase expression in the liver of both non-hyperlipidaemic and P-407-induced hyperlipidaemic mice. Lastly, mice pretreated with mannan before the induction of hyperlipidaemia with P-407 showed a significant reduction in the serum concentration of atherogenic LDL cholesterol, total cholesterol, triglycerides and liver triglycerides. CONCLUSIONS: It is suggested that mannan serotype A, like β-glucan, may represent another hypolipidaemic agent, which could potentially be used as an adjunctive therapy with conventional antihyperlipidaemic drugs (statins and fibrates) in humans.
OBJECTIVES: We evaluated the hypolipidaemic effect of mannanCandida albicans serotype A, relative to atorvastatin, in a mouse model of hyperlipidaemia. METHODS:Mannan serotype A was investigated in vitro and in vivo to determine its effects on macrophage proliferation, nitric oxide (NO) production by cultured macrophages, serum and liver lipids, changes in liver morphology and serum chitotriosidase activity and its expression in the liver. KEY FINDINGS:Mannan serotype A stimulates the macrophage proliferation and NO production in murine peritoneal macrophages in vitro. The activity of serum chitotriosidase (an enzyme released from the activated macrophages) was found to be significantly increased in P-407-induced hyperlipidaemic mice pretreated with low-dose mannan compared with mice administered P-407 only. Mannan treatment in mice was shown to significantly increase the chitotriosidase expression in the liver of both non-hyperlipidaemic and P-407-induced hyperlipidaemic mice. Lastly, mice pretreated with mannan before the induction of hyperlipidaemia with P-407 showed a significant reduction in the serum concentration of atherogenic LDL cholesterol, total cholesterol, triglycerides and liver triglycerides. CONCLUSIONS: It is suggested that mannan serotype A, like β-glucan, may represent another hypolipidaemic agent, which could potentially be used as an adjunctive therapy with conventional antihyperlipidaemic drugs (statins and fibrates) in humans.
Authors: Tatiana A Korolenko; Marina V Ovsyukova; Nataliya P Bgatova; Igor D Ivanov; Svetlana I Makarova; Valentin A Vavilin; Alexey V Popov; Ekaterina I Yuzhik; Elena V Koldysheva; Erik C Korolenko; Evgeny L Zavjalov; Tamara G Amstislavskaya Journal: Life (Basel) Date: 2022-03-17